News
France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...
Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer ...
Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio ...
Hosted on MSN24d
Sanofi to Acquire Blueprint Medicines for $9.1 Billion - MSNSanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...
Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...
Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...
Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...
During a talk at the recent Jefferies Global Healthcare Conference, Cogent CEO Andy Robbins said Blueprint Medicines’ Ayvakit ...
6d
Pharmaceutical Technology on MSNDoH – Abu Dhabi and Sanofi link for vaccine developmentThe Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine ...
Sanofi SAN-0.18%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.16%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results